1 week Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates Zacks

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 18.75% and 45.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?